Semaglutide (GLP-1 Agonist)

Semaglutide represents a significant advancement in metabolic medicine, originally developed for type 2 diabetes management but increasingly studied for its broader health and longevity implications. Research indicates this GLP-1 receptor agonist not only provides excellent glycemic control but also demonstrates substantial cardiovascular benefits, with studies suggesting reduced risk of major adverse cardiovascular events. The compound's ability to promote significant weight loss–averaging 15-20% of body weight in clinical trials–has positioned it as a powerful tool for addressing obesity-related metabolic dysfunction that accelerates aging processes.

Beyond its metabolic effects, emerging research suggests semaglutide may influence multiple longevity pathways. Studies indicate potential neuroprotective effects, with some research exploring its role in cognitive function and neurodegenerative disease prevention. The drug's anti-inflammatory properties and effects on cellular metabolism may contribute to healthspan extension, though long-term longevity outcomes require further investigation. Clinical trials have consistently demonstrated its safety profile, with gastrointestinal side effects being the most common concern, typically diminishing with continued use.

The growing body of evidence supporting semaglutide's multifaceted benefits has sparked interest in the longevity community, particularly given its FDA approval and established safety record. However, research indicates the intervention requires ongoing medical supervision due to potential side effects and the need for dose titration. While primarily prescribed for diabetes and weight management, off-label use for longevity purposes is increasing, though this remains an area where long-term outcomes data is still developing.